BIRC5 and glioblastoma: Su et al. demonstrated that zotiraciclib (a multi-kinase inhibitor that primarily targets CDK9) suppressed phosphorylation of CDK9 and RNA Pol II in glioblastoma cells, which resulted in decreased transcription of anti-apoptotic proteins such as MCL-1 and Survivin (encoded by BIRC5) and induced activation of caspase-3, resulting in cell apoptosis [35].